Biosketch

Paul J Thornalley (PhD Biochemistry, University of Oxford, UK) holds Executive Director/Director appointments in GloVitality Ltd (London, UK; Glovitality.com), Glocentrica Ltd (West Midlands, UK; Glocentrica.com) and iDiagnostix Ltd (West Midlands, UK; iDiagnostix.com). He is a leading researcher and advocate in studies of the pathogenesis associated with hyperglycemia and also the reactive glucose-derived metabolite, methylglyoxal, and its metabolism by glyoxalase 1 (Glo1) of the glyoxalase system – in which he is considered founding investigator. He recently developed the “Hexokinase-linked glycolytic overload” hypothesis of hyperglycemia-induced pathogenesis in hepatic and peripheral insulin resistance, beta-cell glucotoxicity, impaired incretin effect, type 2 diabetes, diabetic vascular complications and associated brain disorders (mild cognitive decline and dementia, Parkinson’s disease and stroke). He also identified increased methylglyoxal as a major physiological activator of the unfolded protein response. He originated the strategy for development of small molecule inducers of Glo1 expression or “Glo1 inducer” therapeutics through activation of transcription factor Nrf2 (leading supplement now called GlucoRegulate) for treatment of insulin resistance and glycolytic overload related conditions. This was proven effective in correcting insulin resistance in subjects living with overweight and obesity in clinical trial. He is founder and Chair of the Reactive Metabolites in Diabetes Study Group, 2014 – date. He has 587 research publications with over 49,000 citations; h-index 115 (Google Scholar) and in the top 1% of scientists globally by citation number (AD Scientific index)